Pacira (PCRX) BioSciences announced new data from its ongoing Phase 1 study of its gene therapy candidate PCRX-201. The data is being presented at the 2025 European Alliance of Associations for Rheumatology, EULAR, Annual Congress, taking place from June 11-14, in Barcelona, Spain.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX: